Identification of germline lymphoma-predisposing variants correlates with significantly earlier age of cancer diagnosis in pediatric patients.
Such variants impact survival outcomes variably depending on specific genetic alterations and lymphoma subtypes.
Integration of germline genetic testing into pediatric lymphoma care may facilitate risk stratification and tailored therapy.
Current evidence underscores the need for further research into mechanistic pathways linking germline mutations with lymphoma pathogenesis and prognosis.
